Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke

Abstract

BackgroundWhile neurogranin has no value as plasma biomarker for Alzheimer’s disease, it may be a potential blood biomarker for traumatic brain injury. This evokes the question whether there are changes in neurogranin levels in blood in other conditions of brain injury, such as acute ischemic stroke (AIS).MethodsWe therefore explored neurogranin in paired cerebrospinal fluid (CSF)/plasma samples of AIS patients (n = 50) from a well-described prospective study. In parallel, we investigated another neuronal protein, i.e. tau, which has already been suggested as potential AIS biomarker in CSF and blood. ELISA as well as Single Molecule Array (Simoa) technology were used for the biochemical analyses. Statistical analyses included Shapiro-Wilk testing, Mann-Whitney analyses and Pearson’s correlation analysis.ResultsIn contrast to tau, of which high levels in both CSF and plasma were related to stroke characteristics like severity and long-term outcome, plasma neurogranin levels were only correlated with infarct volume. Likewise, CSF neurogranin levels were significantly higher in patients with an infarct volume > 5 mL than in patients with smaller infarct volumes. Finally, neurogranin and tau were significantly correlated in CSF, whereas a weaker relationship was observed in plasma.ConclusionsThese findings indicate that although plasma and CSF neurogranin may reflect the volume of acute cerebral ischemia, this synaptic protein is less likely to be a potential AIS biomarker. Levels of tau correlated with severity and outcome of stroke in both plasma and CSF, in the present study as well as previous reports, confirming the potential of tau as an AIS biomarker.Electronic supplementary materialThe online version of this article (10.1186/s12883-017-0945-8) contains supplementary material, which is available to authorized users.

From Stroke to Dementia: a Comprehensive Review Exposing Tight Interactions Between Stroke and Amyloid-β Formation

“…Furthermore, increase of oxidative or nitrosative stress, reduced antioxidant levels, and mitochondrial damage may also play major roles in the development and progression of AD [169]. Tau has been identified as a marker of poor outcome after stroke [170]. Its release may increase the excitotoxicity cascade through stimulation of glutamatergic receptors at the synapse and further progress neurodegeneration after stroke [171].…”

Plasma total‐tau as a biomarker of stroke risk in the community

“…A previous study of 50 acute ischemic stroke patients reported that plasma t-tau levels peaked 7 days poststroke. 12 Moreover, higher plasma t-tau was related to greater stroke severity, poorer stroke outcomes, and larger infarct volumes. Thus, levels of plasma t-tau may increase in response to vascular brain injury and other brain insults.…”

Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases

“…There are robust indications that NF‐L, Tau, and GFAP levels in the CSF and in the blood are strongly correlated so that blood levels, easily accessible, could be used in the diagnosis of neurological disorders, making LP, with its inherent risks, unnecessary. A future confirmatory study in a population like ours should therefore contemplate investigating brain damage markers also in the blood.…”